Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 303

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 303
---
 compensation expense—— —— —— —— —— 647 — — 647 Unrealized loss on marketable securities—— —— —— —— —— — (8)— (8)Net loss—— —— —— —— —— — — (11,847)(11,847)Balance at March 31, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 3,102,869$3 $5,167 $(8)$(131,245)$(126,083)Exercise of common stock options————————31,715—38——38 Vesting of restricted common stock awards————————45,665————— Stock-based compensation expense——————————971——971 Unrealized loss on marketable securities———————————(148)—(148)Net loss————————————(8,552)(8,552)Balance at June 30, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 3,180,249$3 $6,176 $(156)$(139,797)$(133,774)  Exercise of common stock from IPR&D acquisition————————1,414,44528,637——8,639 Exercise of common stock options————————23,270—72——72 Vesting of restricted common stock awards————————45,660————— Stock-based compensation expense——————————1,026——1,026 Unrealized gain on marketable securities———————————929 —929 Net loss————————————(25,441)(25,441)Balance at September 30, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 4,663,624$5 $15,911 $773 $(165,238)$(148,549)

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-4

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (